{"id":"https://openalex.org/W4388600136","doi":"https://doi.org/10.1093/eurheartj/ehad655.2526","title":"PCSK9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: a systematic review and meta-analysis","display_name":"PCSK9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: a systematic review and meta-analysis","publication_year":2023,"publication_date":"2023-11-01","ids":{"openalex":"https://openalex.org/W4388600136","doi":"https://doi.org/10.1093/eurheartj/ehad655.2526"},"language":"en","primary_location":{"id":"doi:10.1093/eurheartj/ehad655.2526","doi":"https://doi.org/10.1093/eurheartj/ehad655.2526","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1093/eurheartj/ehad655.2526","pdf_url":"https://academic.oup.com/eurheartj/article-pdf/44/Supplement_2/ehad655.2526/53608997/ehad655.2526.pdf","source":{"id":"https://openalex.org/S181568219","display_name":"European Heart Journal","issn_l":"0195-668X","issn":["0195-668X","1522-9645"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Heart Journal","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://academic.oup.com/eurheartj/article-pdf/44/Supplement_2/ehad655.2526/53608997/ehad655.2526.pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"A Khan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I27804330","display_name":"Brown University","ror":"https://ror.org/05gq02987","country_code":"US","type":"education","lineage":["https://openalex.org/I27804330"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"A Khan","raw_affiliation_strings":["Brown University , Providence , United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Brown University , Providence , United States of America","institution_ids":["https://openalex.org/I27804330"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077558600","display_name":"Phinnara Has","orcid":"https://orcid.org/0000-0003-4052-221X","observed_orcids":["https://orcid.org/0000-0003-4052-221X"]},"institutions":[{"id":"https://openalex.org/I27804330","display_name":"Brown University","ror":"https://ror.org/05gq02987","country_code":"US","type":"education","lineage":["https://openalex.org/I27804330"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"P Has","raw_affiliation_strings":["Brown University , Providence , United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Brown University , Providence , United States of America","institution_ids":["https://openalex.org/I27804330"]}]},{"author_position":"middle","author":{"id":null,"display_name":"A Jacobson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I27804330","display_name":"Brown University","ror":"https://ror.org/05gq02987","country_code":"US","type":"education","lineage":["https://openalex.org/I27804330"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"A Jacobson","raw_affiliation_strings":["Brown University , Providence , United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Brown University , Providence , United States of America","institution_ids":["https://openalex.org/I27804330"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088336404","display_name":"Stephanie Bogin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I27804330","display_name":"Brown University","ror":"https://ror.org/05gq02987","country_code":"US","type":"education","lineage":["https://openalex.org/I27804330"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"S Bogin","raw_affiliation_strings":["Brown University , Providence , United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Brown University , Providence , United States of America","institution_ids":["https://openalex.org/I27804330"]}]},{"author_position":"middle","author":{"id":null,"display_name":"M Khalid","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2800640726","display_name":"Miriam Hospital","ror":"https://ror.org/053exzj86","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2800640726"]},{"id":"https://openalex.org/I4210151747","display_name":"Lifespan","ror":"https://ror.org/04yt1rh21","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210151747"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"M Khalid","raw_affiliation_strings":["Rhode Island and Miriam Hospitals, Lifespan Cardiovascular Institute , Providence , United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Rhode Island and Miriam Hospitals, Lifespan Cardiovascular Institute , Providence , United States of America","institution_ids":["https://openalex.org/I2800640726","https://openalex.org/I4210151747"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100654651","display_name":"Sarah Kim","orcid":"https://orcid.org/0000-0002-9179-0735","observed_orcids":["https://orcid.org/0000-0002-9179-0735","https://orcid.org/0009-0000-4001-2899"]},"institutions":[{"id":"https://openalex.org/I4387153466","display_name":"Weill Cornell Medicine","ror":"https://ror.org/02r109517","country_code":"US","type":"education","lineage":["https://openalex.org/I205783295","https://openalex.org/I4387153466"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"S Kim","raw_affiliation_strings":["Weill Cornell Medical College , New York , United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Weill Cornell Medical College , New York , United States of America","institution_ids":["https://openalex.org/I4387153466"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083998516","display_name":"Sebhat A. Erqou","orcid":"https://orcid.org/0000-0001-6763-3804","observed_orcids":["https://orcid.org/0000-0001-6763-3804"]},"institutions":[{"id":"https://openalex.org/I27804330","display_name":"Brown University","ror":"https://ror.org/05gq02987","country_code":"US","type":"education","lineage":["https://openalex.org/I27804330"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"S Erqou","raw_affiliation_strings":["Brown University , Providence , United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Brown University , Providence , United States of America","institution_ids":["https://openalex.org/I27804330"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044426165","display_name":"Karen E. Aspry","orcid":"https://orcid.org/0000-0002-8967-660X","observed_orcids":["https://orcid.org/0000-0002-8967-660X"]},"institutions":[{"id":"https://openalex.org/I27804330","display_name":"Brown University","ror":"https://ror.org/05gq02987","country_code":"US","type":"education","lineage":["https://openalex.org/I27804330"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"K Aspry","raw_affiliation_strings":["Brown University , Providence , United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Brown University , Providence , United States of America","institution_ids":["https://openalex.org/I27804330"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010629610","display_name":"Wen\u2010Chih Wu","orcid":"https://orcid.org/0000-0002-2834-2024","observed_orcids":["https://orcid.org/0000-0002-2834-2024"]},"institutions":[{"id":"https://openalex.org/I27804330","display_name":"Brown University","ror":"https://ror.org/05gq02987","country_code":"US","type":"education","lineage":["https://openalex.org/I27804330"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"W Wu","raw_affiliation_strings":["Brown University , Providence , United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Brown University , Providence , United States of America","institution_ids":["https://openalex.org/I27804330"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5005973854","display_name":"Tasnim F. Imran","orcid":"https://orcid.org/0000-0003-2089-8244","observed_orcids":["https://orcid.org/0000-0003-2089-8244"]},"institutions":[{"id":"https://openalex.org/I27804330","display_name":"Brown University","ror":"https://ror.org/05gq02987","country_code":"US","type":"education","lineage":["https://openalex.org/I27804330"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"T F Imran","raw_affiliation_strings":["Brown University , Providence , United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Brown University , Providence , United States of America","institution_ids":["https://openalex.org/I27804330"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":4238,"currency":"EUR","value_usd":4584},"apc_paid":null,"fwci":0.267,"has_fulltext":true,"cited_by_count":1,"citation_normalized_percentile":{"value":0.57990958,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":90,"max":94},"biblio":{"volume":"44","issue":"Supplement_2","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10394","display_name":"Lipoproteins and Cardiovascular Health","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10394","display_name":"Lipoproteins and Cardiovascular Health","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12955","display_name":"Atherosclerosis and Cardiovascular Diseases","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11618","display_name":"Cholesterol and Lipid Metabolism","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pcsk9-inhibitors","display_name":"PCSK9 inhibitors","score":0.9990000128746033},{"id":"https://openalex.org/keywords/inclisiran","display_name":"inclisiran","score":0.9039999842643738},{"id":"https://openalex.org/keywords/evolocumab","display_name":"evolocumab","score":0.984000027179718},{"id":"https://openalex.org/keywords/alirocumab","display_name":"alirocumab","score":0.9959999918937683},{"id":"https://openalex.org/keywords/ldl-cholesterol-lowering","display_name":"LDL cholesterol lowering","score":0.8790000081062317},{"id":"https://openalex.org/keywords/major-adverse-cardiovascular-events","display_name":"major adverse cardiovascular events","score":0.9350000023841858},{"id":"https://openalex.org/keywords/atherosclerotic-cardiovascular-disease","display_name":"atherosclerotic cardiovascular disease","score":0.9079999923706055},{"id":"https://openalex.org/keywords/cardiovascular-risk-reduction","display_name":"cardiovascular risk reduction","score":0.6679999828338623},{"id":"https://openalex.org/keywords/all-cause-mortality","display_name":"all-cause mortality","score":0.7139999866485596},{"id":"https://openalex.org/keywords/residual-cardiovascular-risk","display_name":"residual cardiovascular risk","score":0.5720000267028809},{"id":"https://openalex.org/keywords/statin-therapy","display_name":"statin therapy","score":0.6650000214576721},{"id":"https://openalex.org/keywords/primary-and-secondary-prevention","display_name":"primary and secondary prevention","score":0.6890000104904175},{"id":"https://openalex.org/keywords/ldl-c-thresholds","display_name":"LDL-C thresholds","score":0.42399999499320984},{"id":"https://openalex.org/keywords/lipid-lowering-therapy","display_name":"lipid-lowering therapy","score":0.5239999890327454},{"id":"https://openalex.org/keywords/hypercholesterolemia","display_name":"hypercholesterolemia","score":0.6610000133514404}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9152511358261108},{"id":"https://openalex.org/C2778114629","wikidata":"https://www.wikidata.org/wiki/Q15623825","display_name":"Evolocumab","level":5,"score":0.8552724123001099},{"id":"https://openalex.org/C2780948078","wikidata":"https://www.wikidata.org/wiki/Q21130010","display_name":"PCSK9","level":5,"score":0.7414544820785522},{"id":"https://openalex.org/C2780902209","wikidata":"https://www.wikidata.org/wiki/Q4726914","display_name":"Alirocumab","level":5,"score":0.6547183990478516},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6524961590766907},{"id":"https://openalex.org/C2780739214","wikidata":"https://www.wikidata.org/wiki/Q6723023","display_name":"Mace","level":4,"score":0.6493306756019592},{"id":"https://openalex.org/C2776839432","wikidata":"https://www.wikidata.org/wiki/Q954845","display_name":"Statin","level":2,"score":0.5749111175537109},{"id":"https://openalex.org/C95190672","wikidata":"https://www.wikidata.org/wiki/Q815382","display_name":"Meta-analysis","level":2,"score":0.5301255583763123},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.46981316804885864},{"id":"https://openalex.org/C156957248","wikidata":"https://www.wikidata.org/wiki/Q1862216","display_name":"Odds ratio","level":2,"score":0.45560187101364136},{"id":"https://openalex.org/C2780499067","wikidata":"https://www.wikidata.org/wiki/Q415159","display_name":"Rosuvastatin","level":2,"score":0.44623854756355286},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.41102293133735657},{"id":"https://openalex.org/C164705383","wikidata":"https://www.wikidata.org/wiki/Q10379","display_name":"Cardiology","level":1,"score":0.34902554750442505},{"id":"https://openalex.org/C2778163477","wikidata":"https://www.wikidata.org/wiki/Q43656","display_name":"Cholesterol","level":2,"score":0.24499714374542236},{"id":"https://openalex.org/C62746215","wikidata":"https://www.wikidata.org/wiki/Q14890615","display_name":"Apolipoprotein B","level":3,"score":0.2223682999610901},{"id":"https://openalex.org/C500558357","wikidata":"https://www.wikidata.org/wiki/Q12152","display_name":"Myocardial infarction","level":2,"score":0.20041000843048096},{"id":"https://openalex.org/C43554185","wikidata":"https://www.wikidata.org/wiki/Q425649","display_name":"LDL receptor","level":4,"score":0.14709347486495972},{"id":"https://openalex.org/C2780072125","wikidata":"https://www.wikidata.org/wiki/Q28350","display_name":"Lipoprotein","level":3,"score":0.10727128386497498},{"id":"https://openalex.org/C2780400711","wikidata":"https://www.wikidata.org/wiki/Q2008344","display_name":"Percutaneous coronary intervention","level":3,"score":0.06798946857452393},{"id":"https://openalex.org/C2780745583","wikidata":"https://www.wikidata.org/wiki/Q1316030","display_name":"Apolipoprotein A1","level":4,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1093/eurheartj/ehad655.2526","doi":"https://doi.org/10.1093/eurheartj/ehad655.2526","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1093/eurheartj/ehad655.2526","pdf_url":"https://academic.oup.com/eurheartj/article-pdf/44/Supplement_2/ehad655.2526/53608997/ehad655.2526.pdf","source":{"id":"https://openalex.org/S181568219","display_name":"European Heart Journal","issn_l":"0195-668X","issn":["0195-668X","1522-9645"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Heart Journal","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1093/eurheartj/ehad655.2526","doi":"https://doi.org/10.1093/eurheartj/ehad655.2526","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1093/eurheartj/ehad655.2526","pdf_url":"https://academic.oup.com/eurheartj/article-pdf/44/Supplement_2/ehad655.2526/53608997/ehad655.2526.pdf","source":{"id":"https://openalex.org/S181568219","display_name":"European Heart Journal","issn_l":"0195-668X","issn":["0195-668X","1522-9645"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Heart Journal","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"score":0.8700000047683716,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Systematic Review","id":"https://openalex.org/study-designs/systematic-review"},{"display_name":"Meta-Analysis","id":"https://openalex.org/study-designs/meta-analysis"}],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4388600136.pdf","grobid_xml":"https://content.openalex.org/works/W4388600136.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4389372257","https://openalex.org/W7150734319","https://openalex.org/W4417525514","https://openalex.org/W3008252039","https://openalex.org/W3205307057","https://openalex.org/W2922111129","https://openalex.org/W7196942871","https://openalex.org/W4365483444","https://openalex.org/W4414526568","https://openalex.org/W3093906897"],"abstract_inverted_index":{"Abstract":[0],"Background":[1],"Atherosclerotic":[2],"cardiovascular":[3,373,440],"disease":[4],"(ASCVD)":[5],"is":[6],"the":[7,106,164,203,321,433],"leading":[8],"cause":[9],"of":[10,52,82,94,105,108,143,157,262,316,323,435],"morbidity":[11],"and":[12,36,77,85,103,111,120,132,148,168,173,191,198,222,245,254,275,299,353,393,416,430,437,441],"mortality":[13,374,385],"globally.":[14],"Despite":[15],"Class":[16],"IA":[17],"indications":[18],"for":[19,152,409],"high":[20],"intensity":[21],"statin":[22,53],"therapies":[23,84],"in":[24,178,212,425],"those":[25],"with":[26,43,185,235,257],"ASCVD":[27,78],"or":[28,48,64,154],"at":[29],"risk,":[30],"they":[31],"are":[32,89],"underutilized":[33],"and/or":[34],"insufficient,":[35],"large":[37],"proportions":[38],"remain":[39],"above":[40],"LDL-C":[41,76,118,179,207,267,278,289,303,422],"thresholds":[42],"residual":[44],"risk.":[45],"As":[46],"monotherapy":[47],"on":[49,117],"a":[50,100,260,314],"background":[51],"therapy,":[54],"Proprotein":[55],"convertase":[56],"subtilisn/kexin":[57],"type":[58],"9":[59],"(PCSK9)":[60],"inhibitors":[61,110,145,221,413],"(Evolocumab,":[62,146,414],"Alirocumab)":[63,147,415],"small":[65,112],"interfering":[66,113],"RNA":[67,114],"(siRNA)":[68,115],"therapy":[69,116,150,418],"(Inclisiran)":[70,151,419],"have":[71],"been":[72,407],"demonstrated":[73],"to":[74,98],"lower":[75],"events,":[79],"but":[80],"meta-analyses":[81],"these":[83],"their":[86],"individual":[87],"outcomes":[88],"lacking.":[90],"Purpose":[91],"The":[92],"purpose":[93],"this":[95],"study":[96],"was":[97,196,200,210],"perform":[99],"systematic":[101],"review":[102],"meta-analysis":[104],"effects":[107],"PCSK9":[109,144,220,412],"reduction":[119],"major":[121],"adverse":[122],"cardiac":[123],"events":[124],"(MACE).":[125],"Methods":[126],"Using":[127,159],"Pubmed,":[128],"Embase,":[129],"Cochrane":[130],"Library":[131],"clinicaltrials.gov":[133],"until":[134],"Jan":[135],"2023,":[136],"we":[137,162],"extracted":[138],"randomized":[139],"controlled":[140],"trials":[141],"(RCTs)":[142,214],"siRNA":[149,224,417],"primary":[153],"secondary":[155],"prevention":[156],"MACE.":[158],"random-effects":[160],"models,":[161],"pooled":[163],"relative":[165],"risks":[166],"(RR)":[167],"95%":[169,186],"confidence":[170],"intervals":[171],"(CI)":[172],"weighted":[174],"least-squares":[175],"mean":[176],"difference":[177],"levels.":[180],"We":[181],"estimated":[182],"odds":[183],"ratios":[184],"CIs":[187],"among":[188],"MACE":[189,395,404,444,447],"subtypes":[190],"all-cause":[192,384,442],"mortality.":[193],"Fixed-effect":[194],"model":[195],"used,":[197],"heterogeneity":[199],"assessed":[201],"using":[202],"I2":[204],"statistic.":[205],"Results":[206],"percentage":[208],"change":[209],"reported":[211,408],"47":[213],"(n":[215,230,239,248],"=":[216,231,240,249,297,311,351,371,382,401],"267,900)":[217],"evaluating":[218],"two":[219],"one":[223],"therapy.":[225],"Of":[226],"those,":[227],"21":[228],"studies":[229,247],"211,058)":[232],"included":[233,242,251],"treatment":[234],"Evolocumab":[236,265,319,431],"(140mg),":[237],"22":[238],"47,320)":[241],"Alirocumab":[243,276,363,429,438],"(75mg),":[244],"4":[246],"9,522)":[250],"Inclisiran":[252,286,300],"(284mg":[253],"300mg).":[255],"Compared":[256],"placebo,":[258],"after":[259],"median":[261,315],"24":[263],"weeks,":[264],"reduced":[266,277,288,302,320,364,439],"by":[268,279,290,304,423],"-61.09%":[269],"(95%":[270,281,292,306,329,338,346,358,377,388],"CI:":[271,282,293,307,330,339,347,359,378,389],"-64.81,":[272],"-57.38,":[273],"p<0.01)":[274],"-46.35%":[280],"-51.75,":[283],"-41.13,":[284],"p<0.01).":[285,362],"284mg":[287],"-54.83%":[291],"-59.04,":[294],"-50.62,":[295],"p":[296,310,350,370,381,400],"0.05)":[298],"300mg":[301],"-43.11%":[305],"-52.42,":[308],"-33.80,":[309],"0.01).":[312,402],"After":[313],"26":[317],"months,":[318],"risk":[322,434],"myocardial":[324],"infarction":[325],"(MI),":[326],"OR":[327,336,344,356,366,375,386,396],"0.72":[328],"0.64,":[331],"0.81,":[332],"p<0.01),":[333,342,392],"coronary":[334],"revascularization,":[335],"0.77":[337],"0.70,":[340],"0.84,":[341,391],"stroke,":[343],"0.79":[345],"0.66,":[348],"0.94,":[349],"0.01)":[352],"overall":[354,394],"MACE,":[355,436],"0.85":[357],"0.80,":[360],"0.89,":[361],"MI,":[365],"0.57":[367],"(0.38,":[368],"0.86,":[369],"0.01),":[372,383],"0.35":[376,397],"0.16,":[379],"0.77,":[380,399],"0.60":[387],"0.43,":[390],"(0.16,":[398],"Insufficient":[403],"data":[405],"has":[406],"Inclisiran.":[410],"Conclusion":[411],"significantly":[420],"reduce":[421,432],">40%":[424],"high-risk":[426],"individuals.":[427],"Additionally,":[428],"mortality.Evolocumab":[443],"Forest":[445,448],"PlotsAlirocumab":[446],"Plots":[449]},"counts_by_year":[{"year":2025,"cited_by_count":1}],"updated_date":"2026-10-29T09:56:32.521200","created_date":"2023-11-12T00:00:00"}